20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Recommended Webinars & Conferences

21st World Hematology Congress

Madrid, Spain

29th International Oncology Summit

Chicago, USA

37th Global Summit on Pediatrics

Madrid, Spain

14th Annual Conference on Stem Cells and Regenerative Medicine

Kuala Lumpur, Malaysia
Journal Flyer
Flyer image

Abstract

Association between Treatment Response and Potential Indicators of Efficacy and Safety in a Phase III Trial of Decitabine in Older Patients with Acute Myeloid Leukemia

Mark D. Minden, Christopher Arthur, Jiří Mayer, Mark M. Jones, Erhan Berrak and Hagop Kantarjian

Objective: In a phase III trial, 485 patients aged 65 years or older with newly diagnosed acute myeloid leukemia received decitabine (20 mg/m2 intravenously for 5 days) or treatment of choice (supportive care or cytarabine 20 mg/m2 subcutaneously for 10 days) every 4 weeks. This post hoc analysis investigated potential efficacy and safety indicators and treatment response.

Methods: Transfusions, intravenous antibiotics, and dose modifications were tabulated for responders (morphologic complete remission, complete remission with incomplete blood count recovery, or partial response) and nonresponders.

Results: Median overall survival was significantly greater for treatment responders than for nonresponders (17.4 months vs 4.3 months; P<0.0001). Nonresponders had more intravenous antibiotic use (P=0.024), dose modifications per cycle (P=0.016), and platelet or red blood cell transfusions per cycle (P<0.0001).

Conclusions: Response to decitabine or to treatment of choice may be associated with certain indicators in older patients with acute myeloid leukemia.